Red Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for ...

Filament Health will supply its standardized, patented PEX010 botanical psilocybin drug candidate, produced using proprietary extraction and stabilization methods to an independently sponsored UCSF ...
Finanznachrichten

RED LIGHT HOLLAND CORP

Toronto, Ontario--(Newsfile Corp. - May 14, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario based organization advancing innovation ...
Seeking Alpha

Red Light Holland Announces Filament Health Obtains Interim Order for Proposed Arrangement

Toronto, Ontario--(Newsfile Corp. - March 23, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health ...
Nasdaq

Red Light Holland Provides Timing for 2025 Audited Year-End Results and Announces Live Q&A

Red Light Holland will release its 2025 audited year-end results, prior to the opening of the financial markets on Tuesday, July 29th, 2025 Neither the Canadian Securities Exchange nor its Market ...
Seeking Alpha

PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development

VANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and ...
Nasdaq

Red Light Holland to Head Sponsor Psy-Fi Festival in The Netherlands from September 14-18, 2022, One Of The Largest Psy-Trance Festivals In Europe

Toronto, Ontario--(Newsfile Corp. - July 13, 2022) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in ...
Benzinga.com

Red Light Holland Q1 Revenue Spikes Nearly 30% YoY, Focuses On Strategic Profitability

Red Light Holland reported a 29.7% year-over-year increase in revenue to CAA$1.5 million in Q1 2025. Net loss amounted to CA$1.4 million in Q1 2025, down from CA$1.9 net loss in the corresponding ...

Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate

The expanded agreement adds Filament Health, a wholly owned subsidiary of Red Light Holland, as a supplying affiliate and introduces a GMP-compliant standardized microdose format of PEX010 supported ...
Stockhouse

Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders

Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light Holland" or the "Company") is pleased to announce that shareholders ...
The Globe and Mail

Red Light Holland's FDA-Compliant, DEA-Registered Partner Irvine Labs Receives First Global Shipment of Psilocybin from Company's Netherlands Facility via USA Controlled ...

Groundbreaking and major precedent setting milestone as first global shipment, via USA Controlled Substances import permit, of naturally occurring Psilocybin from Red Light Holland's facility in ...
The Globe and Mail

Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments

Toronto, Ontario--(Newsfile Corp. - April 24, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is pleased to highlight continued expansion and ...
Finanznachrichten

RED LIGHT HOLLAND CORP

Establishes a vertically integrated platform spanning pharmaceutical-grade botanical drug development and global consumer distribution Adds Filament's extensive intellectual property portfolio, ...